Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models

•One AE2 and one RP2 model explained outcomes after RT in the investigated LA-NSCLC cohort.•Reduce AE2: lower mean esophageal dose particularly when giving concurrent chemo-RT.•Reduce RP2: lower mean lung dose particularly for old patients with pulmonary comorbidity.•Model performance was modest, encouraging incorporation of unaccounted for information.